Peripheral Neuropathy in Children and Adolescents with Insulin-dependent Diabetes Mellitus

Abstract

Objective

Type 1 diabetes mellitus (T1DM) is a chronic immune-mediated disease. Diabetic peripheral neuropathy (DPN) is an important microvascular complication of T1DM. One of the most important risk factors for the development of DPN is poor glycemic control. We evaluated the prevalence of DPN among T1DM patients and determined the association between DPN and glycated hemoglobin (HbA1c) level.

Materials & Methods

The subjects were recruited prospectively upon initial evaluation at Imam Reza Hospital, Mashhad, Iran from Jan 2013 to Jan 2015. Patients with T1DM were selected based on the inclusion criteria (i.e., age of 6≤yr and absence of other co-morbidities). DPN was assessed through electrophysiological studies and neurological examinations, while diabetes control was evaluated by measuring the HbA1c level.

Results

Fifty patients with T1DM were enrolled in this study. The mean diabetes duration of patients was 8.38±3.79 yr (mean age 16.68±6.68 yr). The mean HbA1c level was 8.6±2.1% in patients without DPN and 10.5±3 in those with DPN (P=0.016). Overall, 24% of the subjects were presented with DPN according to nerve conduction velocity study (NCV) findings. A positive correlation was found between NCV and clinical symptoms with signs (P<0.001, r=0.45 and P<0.001, r=0.644, respectively). Sensitivity and specificity of neurological examination for DPN diagnosis were 91.7% and 63.2%, respectively. Poor diabetes control is associated with DPN. Moreover, HbA1c level was used as an index for glycemic control over the past 3 months.

Conclusion

Rigid blood glucose control and periodic neurological examinations were the best strategies to prevent DPN.

Keywords: Type 1 diabetes mellitus; NCV; Diabetic peripheral neuropathy; HbA1c level
Peripheral Neuropathy in Children and Adolescents with Insulin-dependent Diabetes Mellitus

**Introduction**

Type 1 diabetes mellitus (T1DM) is a chronic immune-mediated disease, in which the pancreas ceases to produce enough insulin (1). The overall increase in the incidence of T1DM was estimated at nearly 3%, and the annual incidence of this condition varied from 0.61 cases per 100000 populations in China to 57.6 cases per 100000 in Finland (2, 3). Middle East region, Saudi Arabia and Kuwait have the highest incidence rate at 31.4 and 22.3/100000 per year (4).

Annually, 1 to 35 new cases of T1DM (younger than 14 yr) per 100000 populations are diagnosed per year. In various countries, the incidence rate of T1DM has at least doubled over the past two decades. The incidence of this condition seems to raise as the distance from the equator increases (5, 6).

Peripheral nervous system involvement is a common complication of T1DM, and unlike adults, patient’s polyneuropathy has no clinical manifestations in diabetic children (7). The prevalence of neuropathy varies depending on the severity and duration of hyperglycemia (1). The prevalence of peripheral neuropathy in both adults and children ranges between 7% and 57% (8).

Nerve conduction velocity (NCV) test is the method of choice for the diagnosis of neuropathy. The incidence of neuropathy in different studies ranges from 10% to 68% among diabetic patients (9, 10).

In this study, we evaluated the sign and symptoms of peripheral polyneuropathy and its correlation with glycated hemoglobin (HbA1c) level as an indicator of metabolic control in diabetic patients in Mashhad City, Eastern Iran.

**Materials & Methods**

The subjects were recruited prospectively upon initial evaluation at Imam Reza Hospital, Mashhad, Iran from Jan 2013 to Jan 2015. Patients with T1DM were selected based on the inclusion criteria, i.e., age of six years or older, and absence of other comorbidities. On the other hand, patients with neurological disorders, such as mental retardation, secondary diabetes, systemic diseases, or maturity-onset diabetes of the young were excluded from the study.

Ethics Committee of Mashhad University of Medical Sciences approved this study. Written consent forms were obtained from all study subjects.

Anthropometric data including body mass index (BMI), weight, and height were measured while recruiting the participants. HbA1c level and lipid profile were analyzed by applying the immune turbid metric method (BT3000 analyzer, Italy). An expert neurologist and endocrinologist to determine DPN was carried out a detailed neurological examination. Vibration perception, temperature sensation, pinprick sensation, MMT and ankle reflex were also examined in the participants. A tuning fork (128 Hz), Semmes-Weinstein monofilament test, cold and warm water test, and a reflex hammer were used for the evaluations. Neuropathy was evaluated through electrodiagnostic studies. The reference for evaluation and comparison of the electrodiagnostic parameters of sensorimotor responses were based on the tables from the “Electrodiagnosis in diseases of the nerve and muscle” and “electrodiagnostic medicine”. The evaluation was done in a calm room with optimal lighting and temperature was at 24-degree Celsius. Patients’ skin surface
Peripheral Neuropathy in Children and Adolescents with Insulin-dependent Diabetes Mellitus

The temperature was approximately 34 degrees Celsius, at the time of evaluation.

The sensory nerves evaluated were the median and ulnar nerves in the upper limbs, Sural and superficial peroneal nerves in the lower limbs, and sural as well as superficial peroneal nerves in lower limbs. The methods used for the stimulation, recording, and analysis of the data were based on the standards of the books aforementioned.

NCV and distal latency tests were performed in the following nerves: Common peroneal nerve, tibial nerve, superficial peroneal nerve, and sural (sensory) nerve in the lower extremities, as well as median (motor and sensory) nerves in the upper extremities, were observed in the tests. Electrodiagnostic studies were conducted by one single operator and device (Myto, Italy). We evaluated 50 diabetic patients, divided into two groups: group A with abnormal NCV, and group B with normal NCV.

Normality of variables was tested by Kolmogorov–Smirnov test. Then, parametric or non–parametric tests were performed to determine the difference and relationship between variables. For data analysis, SPSS Ver. 16 (Chicago, IL, USA) was applied, and the collected data with referral codes were imported into the software. P-value less than 0.05 were considered statistically significant.

Results

Fifty T1DM patients with the mean age of 16.68±6.98 yr and disease duration of 8.36±3.79 yr were enrolled (Table 1). Overall, 54% (n=27) of the participants were female. Twenty one (42%) patients were clinically asymptomatic, while 29 (58%) cases had at least one of the signs or symptoms of peripheral neuropathy. Abnormal pain sensation was detected in 9 (18%) patients, and the frequency of paresthesia, numbness, and burning sensation was 6%, 28%, and 8%, respectively; in total, and 30 (60%) patients had one abnormal symptom. Neurological examination was suggestive of impaired temperature sensation in 6 (12%) cases. Reduced vibration perception, abnormal Achilles reflex, and impaired touch perception were reported in 5 (10%), 15 (30%), and 3 (6%) cases, respectively; overall, 29 (58%) patients had one abnormal sign. Abnormal Achilles reflex and numbness were the most common findings in our study population (Table 2).

**Table 1.** Clinical and biochemical characteristics of diabetic patients with and without neuropathy

| Risk factors          | Neuropathy | P-value |
|-----------------------|------------|---------|
|                       | Present | Absent |       |
| Sex (male/female)     | 3/9     | 20/18  | 0.094 |
| Age (yr)              | 19.7±10.1 | 15.7±5.4 | 0.20  |
| Diabetes duration (years) | 11.3±9.4 | 7.4±3.7 | 0.18  |
| BMI (kg/m^2)          | 21.1±2.6 | 19.7±3.3 | 0.16  |
| Triglyceride (mg/dl)  | 105.6±66.5 | 83.7±44.7 | 0.35  |
| Cholesterol (mg/dl)   | 158.3±34.8 | 188.7±64.4 | 0.28  |
| HbA1c                 | 10.58±3.05 | 8.63±2.1 | 0.016 |

Data are presented as Mean±SD

BMI: Body mass index; TG: Triglyceride; TC: Total cholesterol, HbA1c: Glycated hemoglobin
Peripheral Neuropathy in Children and Adolescents with Insulin-dependent Diabetes Mellitus

Based on the comparison between the two groups by Kappa coefficients, clinical signs were not significantly associated with peripheral neuropathy, while a significant correlation was found between peripheral neuropathy and clinical symptoms (Table 3). NCV was normal in 38 (76%) patients and abnormal in 12 (24%) cases. The mean HbA1c level was 8.6±2.1 (mmol/ml) in patients without peripheral neuropathy, and 10.5±3 in those with peripheral neuropathy (P=0.016) (Table 1).

**Discussion**

Diabetic neuropathy is a major complication of T1DM. This term usually refers to polyneuropathy and can be classified into two broad subclinical and clinical stages. The prevalence of diabetic neuropathy in developing countries ranges between 10% and 68% (9,11). In Western countries, up to 60% of all patients with diabetes are affected by diabetic neuropathy (10). However, the estimated rates of children are inaccurate, considering the prevalence of subclinical diabetic neuropathy observation in this age group.

In the present study, DPN was reported in 24% of the patients, according to the electrodiagnostic studies, while 25% of these cases were clinically asymptomatic. Nearly one-fourth of young patients who recently diagnosed with diabetes
Peripheral Neuropathy in Children and Adolescents with Insulin-dependent Diabetes Mellitus

had pathological findings in the distal nerves (9). Moreover, subclinical DPN was reported in up to 60% of patients in Isfahan, Iran (12). Various studies have introduced diabetes duration as a major factor in DPN development (11, 13-16), although this finding has not been confirmed in other studies (17, 18), similar to the present research. On the other hand, diabetic neuropathy and abnormal NCV findings have been reported in patients with recently diagnosed diabetes by some researchers (14, 19).

Patients with diabetic neuropathy have few complaints, and their physical examination may reveal variable degrees of sensory loss (20). In our study, 28% of all subjects experienced numbness and 30% showed abnormal tendon reflex. Reduction in pain perception on neurological examinations, abnormal tendon reflex, and numbness were more significant in-group A, compared to group B. The frequency of abnormal pain sensation, paresthesia, and burning sensation was estimated at 18%, 6%, and 8%, respectively. Neurological examination was suggestive of impaired temperature sensation, reduced pain perception, reduced vibration perception, abnormal tendon reflex, and impaired touch perception in 12%, 0%, 10%, 30%, and 6% of subjects, respectively.

The present findings revealed a positive correlation between clinical symptoms and abnormal NCV with sensitivity of 91.7% and specificity of 84.2% (Table 3). Therefore, serial neurological examinations could be used for the diagnosis of diabetic neuropathy in clinics. Deep peroneal and sural nerves were the most commonly affected nerves in our patients (18); moreover, in two patients, the mentioned diagnosis associated with carpal tunnel syndrome was detected.

Table 3. The correlation between clinical indices and nerve conduction velocity (NCV)

| Abnormal signs | Conduction | Normal NCV N=38 (76%) | Abnormal NCV N=12 (24%) | Kappa coefficient |
|---------------|------------|-----------------------|-------------------------|-------------------|
| Absent        | 24 (63.2)  | 3 (25)                | Kappa=0.290 P-Value=0.021 |
| Present       | 14 (36.8)  | 9 (75)                |                         |
| Total         | 38 (100)   | 12 (100)              |                         |

| Abnormal symptoms | Conduction | Normal NCV N=38 (76%) | Abnormal NCV N=12 (24%) | Kappa coefficient |
|-------------------|------------|-----------------------|-------------------------|-------------------|
| Absent            | 32 (84.2)  | 1 (8.3)               | Kappa=0.664 Sig<0.001   |
| Present           | 6 (15.8)   | 11 (91.7)             |                         |
| Total             | 38 (100)   | 12 (100)              |                         |
Although hyperglycemia plays a crucial role in the progression of DPN, DPN can also occur without hyperglycemia (21, 22). The 24-yr prospective study of 32 newly diagnosed patients with type 1 diabetes and comparing well controlled with poorly controlled patients, showed that near-normoglycemic control from the diagnosis over a 24 yr was associated with a strong prevention of peripheral neuropathy development (23).

Our results revealed that poor diabetes control could be associated with DPN, and HbA1c level, used as an index for glycemic control over the past six months. A previous study has suggested an association between hyperlipidemia and DPN (24); however, in Jaiswal .M et.al study have not confirmed this correlation, similar to the present study(25). The prevalence of diabetic peripheral neuropathy was 7% in youth with type 1 diabetes and risk factors were older age, longer diabetes duration, increased blood pressure, obesity, increased LDL cholesterol and triglycerides (25). In fact, in the present study, diabetic neuropathy had no positive correlation with age, sex, BMI, duration of disease, or hyperlipidemia, whereas a significant correlation between HbA1c level and diabetic neuropathy was observed.

In conclusion, the best strategy to prevent diabetic neuropathy is rigid blood glucose control and periodic neurological examinations and the poor glycemic control is a determining factor in peripheral neuropathy in type 1 diabetic patients.

Acknowledgment

We thank the Vice Chancellor for Research of Mashhad University of Medical Sciences for supporting this research. The authors greatly appreciate for the co-operation of Nooshin Abdollahpour in manuscript draft preparation. (IR.MUMS.REC.1390.30)

Author’s Contribution

Nosrat Ghaemi conceived the original idea
Hossein Hasan Abadi designed the experiments and collected the data
Farah Ashrafzadeh and Somaye Sarvari and Hamid Reza Rahimi carried out analysis of data
Somayyeh Hashemian drafted the manuscript and Nosrat Ghaemi revised it
Somayyeh Hashemian and Nosrat Ghaemi approved the final version that was submitted

All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflicts of interest

The authors declare that there is no conflict of interest.

References

1. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008;120(1):1-34.
2. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med 2006;23(8):857-66.
3. Diana K. Trials in prevention of Type 1 Diabetes: Current and Future.Can J Diabetes 2014; 38(4): 279-284.
4. Brusseles, Belgium: International Diabetes Federation. 6th ed.; 2013. IDF Diabetes Atlas. http://www.idf.org/diabetesatla.
5. Soltesz G, Patterson CC, Dahlquist G.
Worldwide childhood type 1 diabetes incidence—what can we learn from epidemiology? Pediatr Diabetes 2007;8 Suppl 6:6-14.

6. Silink M. Childhood diabetes: a global perspective. Horm Res 2002;57 Suppl 1:1-5.

7. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002;19(5):377-84.

8. Hajas G, Kissova V, Tirpakova A. A 10-yr follow-up study for the detection of peripheral neuropathy in young patients with type 1 diabetes. Pediatric Diabetes 2016;

9. Trotta D, Verrotti A, Salladini C, Chiarelli F. Diabetic neuropathy in children and adolescents. Pediatr Diabetes 2004;5(1):44-57.

10. Sajic S, Petrovic R. Subclinical peripheral neuropathy in type 1 diabetic adolescents and its relationship with metabolic control. Srp Arh Celok Lek 2005;133(7-8):358-62.

11. Bao XH, Wong V, Wang Q, Low LC. Prevalence of peripheral neuropathy with insulin-dependent diabetes mellitus. Pediatr Neurol 1999;20(3):204-9.

12. Hasani N, Khosrawi S, Hashemipour M, Haghighatiyan M, Javdan Z, Taheri MH, et al. Prevalence and related risk-factors of peripheral neuropathy in children with insulin-dependent diabetes mellitus. J Res Med Sci 2013;18(2):132-6.

13. Nelson D, Mah JK, Adams C, Hui S, Crawford S, Darwish H, et al. Comparison of conventional and non-invasive techniques for the early identification of diabetic neuropathy in children and adolescents with type 1 diabetes. Pediatr Diabetes 2006;7(6):305-10.

14. Weintrob N, Amitay I, Lilos P, Shalitin S, Lazar L, Josefsberg Z. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. J Diabetes Complications 2007;21(1):13-9.

15. Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurol 2005;5:24.

16. Riihimaa PH, Suominen K, Tolonen U, Jantti V, Knip M, Tapanainen P. Peripheral nerve function is increasingly impaired during puberty in adolescents with type 1 diabetes. Diabetes Care 2001;24(6):1087-92.

17. Karsidag S, Morali S, Sargin M, Salman S, Karsidag K, Us O. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus. Diabetes Res Clin Pract 2005;67(3):211-9.

18. Meh D, Denislisic M. Subclinical neuropathy in type I diabetic children. Electroencephalogr Clin Neurophysiol 1998;109(3):274-80.

19. Semiz S, Fisenk F, Akcurin S, Bircan I. Temporary multiple cranial nerve palsies in a patient with type 1 diabetes mellitus. Diabetes Metab 2002;28(5):413-6.

20. Malgrange D, Richard JL, Leymarie F. Screening diabetic patients at risk for foot ulceration. A multi-centre hospital-based study in France. Diabetes Metab 2003;29(3):261-8.

21. Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology 2001 13;57(9):1701-4.

22. Kikkawa Y, Kuwabara S, Misawa S, Tamura N, Kitano Y, Ogawara K, et al. The acute effects of
glycemic control on nerve conduction in human diabetics. Clin Neurophysiol 2005;116(2):270-4.

23. Ziegler D, Behler M, Schroers-Teuber M, Roden M. Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open 2015: 5: 1–9.

24. Ji N, Zhang N, Ren ZJ, Jia KB, Wang L, Ni JX, et al. Risk factors and pain status due to diabetic neuropathy in chronic long-term diabetic patients in a Chinese urban population. Chin Med J (Engl) 2012;125(23):4190-6.

25. Jaiswal M, Divers J, Dabela D, Isom S, A.Bell R, L.Martin C, et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care J 2017 1;40(9):1226-32.